Results 251 to 260 of about 4,183,330 (355)
Unlocking therapeutic potential: Targeting lymphocyte activation Gene-3 (LAG-3) with fibrinogen-like protein 1 (FGL1) in systemic lupus erythematosus. [PDF]
Wang B, Zhang B, Wu M, Xu T.
europepmc +1 more source
This study shows that lower NAM levels in PE‐derived pEVs correlate with disease severity. NAM‐deficient pEVs reduce Th1 and Th17 inhibition, leading to PE‐like symptoms. NAM in pEVs inhibits Th1 via SIRT1 and Th17 via macrophages. Reduced NAM in PE‐EVs is due to decreased HRS expression in trophoblasts, resulting from elevated HSP27.
Haiyi Fei +10 more
wiley +1 more source
Illustrating how tumor‐derived PLA2G16 regulates tetracosatetraenoic acid (C24:4 (n‐6)) accumulation and CD8+ T cell activation via the C24:4‐PPARα‐FAO axis in early metastatic niches, thereby promoting lung metastasis of triple‐negative breast cancer.
Yubi Gan +13 more
wiley +1 more source
Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma. [PDF]
Hamid O +31 more
europepmc +1 more source
This study finds that CD8⁺ TSCM cells exhibit superior self‐renewal, differentiation, and antiviral activity. Transcriptome and epigenome analyses highlight MAPK cascade regulation in TSCM cells. In vivo, virus‐specific TSCM cells show enhanced persistence and tumor protection.
Xun‐Hong Cao +13 more
wiley +1 more source
Glutamine deprivation triggers ACSL5 upregulation in tumor cells, sustaining their viability via dual metabolic rewiring programs. ACSL5 enhances glycolysis by relieving p53's inhibition of PGAM1 while also sustaining mitochondrial respiration and TCA cycle flux through promoting IDH2 dimerization.
Shuai Tian +11 more
wiley +1 more source

